Correlation Between Lisata Therapeutics and SAB Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Lisata Therapeutics and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lisata Therapeutics and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lisata Therapeutics and SAB Biotherapeutics, you can compare the effects of market volatilities on Lisata Therapeutics and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lisata Therapeutics with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lisata Therapeutics and SAB Biotherapeutics.

Diversification Opportunities for Lisata Therapeutics and SAB Biotherapeutics

0.16

Correlation Coefficient

Lisata Therapeutics  SAB Biotherapeutics

Average diversification

The 3 months correlation between Lisata and SAB is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Lisata Therapeutics and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and Lisata Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lisata Therapeutics are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of Lisata Therapeutics i.e., Lisata Therapeutics and SAB Biotherapeutics go up and down completely randomly.

Pair Corralation between Lisata Therapeutics and SAB Biotherapeutics

Given the investment horizon of 90 days Lisata Therapeutics is expected to generate 2.27 times more return on investment than SAB Biotherapeutics. However, Lisata Therapeutics is 2.27 times more volatile than SAB Biotherapeutics. It trades about -0.03 of its potential returns per unit of risk. SAB Biotherapeutics is currently generating about -0.14 per unit of risk. If you would invest  313.00  in Lisata Therapeutics on October 26, 2024 and sell it today you would lose (38.00) from holding Lisata Therapeutics or give up 12.14% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Lisata Therapeutics  vs.  SAB Biotherapeutics

Lisata Therapeutics

Risk-Adjusted Performance

1 of 100

Very Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Lisata Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Lisata Therapeutics may actually be approaching a critical reversion point that can send shares even higher in February 2025.

SAB Biotherapeutics

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental drivers, SAB Biotherapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Lisata Therapeutics and SAB Biotherapeutics

The main advantage of trading using opposite Lisata Therapeutics and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lisata Therapeutics position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.

The idea behind Lisata Therapeutics and SAB Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.